Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis

We conducted this largest, single-center, retrospective study to determine the efficacy of sorafenib versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC) in Chinese patients to validate the potential data on direct comparison of the efficacy of first-line treatment with...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Sheng, Xinan, Chi, Zhihong, Cui, Chuanliang, Si, Lu, Li, Siming, Tang, Bixia, Mao, Lili, Lian, Bin, Wang, Xuan, Yan, Xieqiao, Guo, Jun
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5053631/
https://ncbi.nlm.nih.gov/pubmed/26894858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7395
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы